SCHEMBL4430752

SCHEMBL4430752

CC(C)(C)OC(=O)NCCC[C@H](NC(=O)c1cccn(Cc2cc(Cl)cc(Cl)c2)c1=O)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C3AR1 Q16581 1/20 0.46
BRD4 O60885 2/20 0.46
BRD2 P25440 1/20 0.42
BRD3 Q15059 1/20 0.42
BRDT Q58F21 1/20 0.42
KDM4E B2RXH2 3/20 0.42
PDPK1 O15530 1/20 0.42
MAPT P10636 4/20 0.42
POLB P06746 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
TP53 P04637 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
GAA P10253 2/20 0.40
HTT P42858 1/20 0.40
ALDH1A1 P00352 1/20 0.40
RAB9A P51151 1/20 0.40
GRN P28799 1/20 0.40
SORT1 Q99523 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4989827 0.94 MAPT (0.50) C3AR1BRD4BRD2BRD3BRDT
SCHEMBL4989359 0.92 BRD4 (0.54) C3AR1BRD4BRD2BRD3BRDT
SCHEMBL4426839 0.92 C3AR1 (0.47) C3AR1BRD4BRD2BRD3BRDT
SCHEMBL4427249 0.90 C3AR1 (0.44) C3AR1BRD4BRD2BRD3BRDT
SCHEMBL4989511 0.90 BRD4 (0.53) C3AR1BRD4BRD2BRD3BRDT
SCHEMBL4427434 0.89 C3AR1 (0.48) C3AR1BRD4BRD2BRD3BRDT
SCHEMBL4434045 0.89 C3AR1 (0.46) C3AR1BRD4BRD2BRD3BRDT
SCHEMBL4430898 0.88 KDM4E (0.55) C3AR1BRD4BRD2BRD3BRDT
SCHEMBL4428322 0.87 CNR1 (0.49) C3AR1BRD4BRD2BRD3BRDT
SCHEMBL4427448 0.87 C3AR1 (0.51) C3AR1BRD4BRD2BRD3BRDT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2125739-A1 MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2009-12-02 EP disclosed
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof ENCYSIVE PHARMACEUTICALS, INC. 2008-08-07 US disclosed
WO-2008079371-A1 MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof C3AR1, C5, C5AR1 C3AR1 1/4885BRD4 2776/4885BRD2 4008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.